See more : Yes Optoelectronics (Group) Co., Ltd. (002952.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Ocean Biomedical, Inc. (OCEA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocean Biomedical, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Candel Therapeutics, Inc. (CADL) Income Statement Analysis – Financial Results
- Telecom Italia S.p.A. (TIT.BR) Income Statement Analysis – Financial Results
- Sembcorp Marine Ltd (S51.SI) Income Statement Analysis – Financial Results
- Enento Group Oyj (ENENTO.HE) Income Statement Analysis – Financial Results
- Kinder Morgan, Inc. (2KD.DE) Income Statement Analysis – Financial Results
Ocean Biomedical, Inc. (OCEA)
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 33.93M | 49.00K | 35.00K |
| General & Administrative | 0.00 | 28.41M | 1.60M | 197.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.48M | 28.41M | 1.60M | 197.00K |
| Other Expenses | 0.00 | 1.00K | -1.00K | 0.00 |
| Operating Expenses | 2.48M | 62.35M | 1.65M | 232.00K |
| Cost & Expenses | 2.48M | 62.35M | 1.65M | 232.00K |
| Interest Income | 1.52M | 2.45K | 0.00 | 0.00 |
| Interest Expense | 691.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.52M | 236.56K | 206.30K | 171.86K |
| EBITDA | -957.74K | -564.11K | -1.65M | -232.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.48M | -62.35M | -1.65M | -232.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.52M | 61.78M | -1.00K | 0.00 |
| Income Before Tax | -958.43K | -62.34M | -1.65M | -232.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -236.56K | -206.30K | -171.86K |
| Net Income | 565.47K | -62.34M | -1.65M | -232.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -4.71 | -0.08 | -0.01 |
| EPS Diluted | -0.03 | -4.71 | -0.08 | -0.01 |
| Weighted Avg Shares Out | 36.50M | 13.23M | 20.20M | 20.20M |
| Weighted Avg Shares Out (Dil) | 36.50M | 13.23M | 20.20M | 20.20M |
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
3 Trending Biotech Penny Stocks
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
Source: https://incomestatements.info
Category: Stock Reports